Skip to content

News & Media

5th January 2023
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
21st December 2022
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors
12th December 2022
Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting
9th December 2022
Setting the Stage for ASH 2022
7th November 2022
Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a Phase 1/2 Clinical Trial at the 64th ASH Annual Meeting
7th September 2022
Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity – preprint manuscript posted
7th March 2022
Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases
8th October 2021
Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine
25th May 2021
Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University
1st September 2020
Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University
Top